drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Off-the-shelf, gene-modified T cells expressing dual chimeric antigen receptors targeting CD19 and BCMA to deplete B cells, plasmablasts, and plasma cells in autoimmune hemolytic anemia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, off-the-shelf T cells engineered with dual chimeric antigen receptors targeting CD19 and BCMA. Binding to CD19+ B cells and BCMA+ plasmablasts/plasma cells activates the CAR T cells to kill these cells, depleting autoreactive antibody-producing compartments and reducing pathogenic autoantibodies in autoimmune hemolytic anemia.
drug_name
Universal allogeneic anti-CD19/BCMA CAR T cells
nct_id_drug_ref
NCT06733610